Alan Hruza

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/12009442/publications.pdf

Version: 2024-02-01

22 papers	1,894 citations	623734 14 h-index	677142 22 g-index
22 all docs	22 docs citations	22 times ranked	3169 citing authors

#	Article	IF	Citations
1	Discovery of hydroxy pyrimidine Factor IXa inhibitors. Bioorganic and Medicinal Chemistry Letters, 2020, 30, 127279.	2.2	1
2	Discovery of a highly potent orally bioavailable imidazo-[1, 2- a]pyrazine Aurora inhibitor. Bioorganic and Medicinal Chemistry Letters, 2018, 28, 1397-1403.	2.2	4
3	Structure of the insulin receptorâ€“insulin complex by single-particle cryo-EM analysis. Nature, 2018, 556, 122-125.	27.8	184
4	Discovery of 3(S)-thiomethyl pyrrolidine ERK inhibitors for oncology. Bioorganic and Medicinal Chemistry Letters, 2018, 28, 2029-2034.	2.2	11
5	Discovery of novel aminobenzisoxazole derivatives as orally available factor IXa inhibitors. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 2622-2628.	2.2	10
6	Structure of the Insulin Receptor in Complex with Insulin using Single Particle CryoEM Analysis. Microscopy and Microanalysis, 2017, 23, 1186-1187.	0.4	3
7	Discovery of 1-(1H-Pyrazolo[4,3-c]pyridin-6-yl)urea Inhibitors of Extracellular Signal-Regulated Kinase (ERK) for the Treatment of Cancers. Journal of Medicinal Chemistry, 2016, 59, 6501-6511.	6.4	26
8	Dissecting Therapeutic Resistance to ERK Inhibition. Molecular Cancer Therapeutics, 2016, 15, 548-559.	4.1	50
9	Development of a novel class of potent and selective FIXa inhibitors. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 4945-4949.	2.2	16
10	Rapid development of two factor IXa inhibitors from hit to lead. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 2321-2325.	2.2	14
11	Development of a novel tricyclic class of potent and selective FIXa inhibitors. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 5437-5443.	2.2	16
12	Discovery of a Novel ERK Inhibitor with Activity in Models of Acquired Resistance to BRAF and MEK Inhibitors. Cancer Discovery, 2013, 3, 742-750.	9.4	559
13	Synthesis and SAR studies of imidazo-[1,2-a]-pyrazine Aurora kinase inhibitors with improved off-target kinase selectivity. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 3544-3549.	2.2	11
14	Discovery of imidazo[1,2-a]pyrazine-based Aurora kinase inhibitors. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 5170-5174.	2.2	35
15	Discovery of Dinaciclib (SCH 727965): A Potent and Selective Inhibitor of Cyclin-Dependent Kinases. ACS Medicinal Chemistry Letters, 2010, 1, 204-208.	2.8	134
16	Discovery of a Potent, Injectable Inhibitor of Aurora Kinases Based on the Imidazo-[1,2-a]-Pyrazine Core. ACS Medicinal Chemistry Letters, 2010, 1, 214-218.	2.8	31
17	Structureâ€guided discovery of cyclinâ€dependent kinase inhibitors. Biopolymers, 2008, 89, 372-379.	2.4	51
18	Pyrazolo[1,5-a]pyrimidines as orally available inhibitors of cyclin-dependent kinase 2. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 6220-6223.	2.2	49

#	Article	IF	Citations
19	Versatile templates for the development of novel kinase inhibitors: Discovery of novel CDK inhibitors. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 6216-6219.	2.2	32
20	Structural characterization of nitric oxide synthase isoforms reveals striking active-site conservation. Nature Structural Biology, 1999, 6, 233-242.	9.7	397
21	Zinc mediated dimer of human interferon-Î±2b revealed by X-ray crystallography. Structure, 1996, 4, 1453-1463.	3.3	236
22	A homology model of human interferon Î±-2. Proteins: Structure, Function and Bioinformatics, 1993, 17, 62-74.	2.6	24